Debra Stephanie Barker
Director/Board Member bij BERGENBIO ASA
Vermogen: 87 695 $ op 29-02-2024
Profiel
Debra Stephanie Barker is on the board of CureVac SE and 6 other companies.
In her past career Dr. Barker held the position of Chief Medical & Development Officer at Spexis Ltd.
and Global Head-Medical Affairs at Novartis AG.
She received a doctorate from Queens' College Cambridge and a graduate degree from King's College London.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ARIX BIOSCIENCE PLC
0.02% | 03-05-2023 | 26 000 ( 0.02% ) | 46 828 $ | 29-02-2024 |
DESTINY PHARMA PLC
0.09% | 25-05-2023 | 88 461 ( 0.09% ) | 36 367 $ | 29-02-2024 |
CUREVAC N.V.
0.00% | 31-03-2023 | 1 316 ( 0.00% ) | 4 501 $ | 29-02-2024 |
Actieve functies van Debra Stephanie Barker
Bedrijven | Functie | Begin |
---|---|---|
BERGENBIO ASA | Director/Board Member | 13-03-2019 |
DESTINY PHARMA PLC | Director/Board Member | 01-01-2020 |
CUREVAC N.V. | Director/Board Member | 22-06-2022 |
ARIX BIOSCIENCE PLC | Director/Board Member | 10-08-2022 |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Director/Board Member | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Director/Board Member | 01-08-2022 |
Eerdere bekende functies van Debra Stephanie Barker
Bedrijven | Functie | Einde |
---|---|---|
SPEXIS AG | Chief Tech/Sci/R&D Officer | 31-12-2018 |
NOVARTIS AG | Corporate Officer/Principal | - |
Opleiding van Debra Stephanie Barker
King's College London | Graduate Degree |
Queens' College Cambridge | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 5 |
---|---|
NOVARTIS AG | Health Technology |
SPEXIS AG | Health Technology |
DESTINY PHARMA PLC | Health Technology |
BERGENBIO ASA | Health Technology |
ARIX BIOSCIENCE PLC | Finance |
Bedrijven in privébezit | 4 |
---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
CureVac NV | |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |